The EPS miss and lack of revenue reinforce the pre-revenue biotech narrative. Watch for CNTY-813 IND submission in 4Q 2026 and initial clinical data in 2H 2027 as key catalysts. The long cash runway reduces near-term financing risk, but the stock will likely trade on pipeline milestones rather than financials.
Price Chart
Executive Summary
Century Therapeutics reported Q2 2026 EPS of -$0.17, a 55.3% miss vs consensus of -$0.11, with no revenue. The company highlighted progress with CNTY-813 (T1D islet replacement therapy) and CNTY-308 (CAR-iT) but the wider-than-expected loss and absence of near-term catalysts beyond pipeline milestones temper the outlook. Cash runway into 1Q 2029 provides a long operational horizon, but the EPS miss and lack of revenue keep the stock range-bound near-term.
Key Financial Metrics
Key Facts
- EPS of -$0.17 missed consensus of -$0.11 (55.3% miss)
- No revenue reported for Q2 2026
- Cash, cash equivalents, and investments of $197.2M as of June 30, 2026, providing runway into 1Q 2029
- CNTY-813 IND submission on track for 4Q 2026; initial clinical data expected 2H 2027
- CNTY-308 remains on track to enter clinic in 2026
- R&D expenses decreased to $19.6M from $26.9M YoY; G&A expenses decreased to $5.8M from $7.8M YoY
- Net loss widened to $34.6M from $32.5M YoY
Financial Impact
EPS miss of $0.06 vs consensus; net loss of $34.6M
Risk Factors
- Clinical trial delays or negative data for CNTY-813 or CNTY-308
- Dilution risk from potential future equity offerings given ongoing cash burn
- Competitive landscape in T1D cell therapy and CAR-T space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343577 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.42 (−7.19%) |
Oct 2, 2026 24d ago | Press Release | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.42 (−7.19%) |
Sep 22, 2026 4w ago | Institutional Cluster | $1.89 $1.76 | ▼ −6.88% | ▼ −6.16% | $1.42 (−24.87%) |
Sep 10, 2026 6w ago | 3 | $1.94 $2.00 | ▲ +3.09% | ▲ +3.54% | $1.42 (−26.80%) |
Aug 12, 2026 10w ago | 8-K | $1.96 $1.93 | ▼ −1.53% | ▼ −2.23% | $1.42 (−27.55%) |
Aug 12, 2026 10w ago | Press Release | $1.96 $1.93 | ▲ +1.53% | ▲ +2.23% | $1.42 (+27.55%) |
Jun 16, 2026 18w ago | 8-K | $2.25 $2.29 | ▲ +1.78% | ▲ +1.00% | $1.42 (−36.89%) |
Jun 15, 2026 19w ago | Insider Cluster | $2.18 $2.25 | ▲ +3.21% | ▲ +4.46% | $1.42 (−34.86%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.42 (−33.02%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.42 (−33.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers